UCB's anti-IL-6 mAb meets Phase IIb RA endpoint

UCB Group (Euronext:UCB) said subcutaneous olokizumab met the primary endpoint vs. placebo in a Phase IIb trial to treat moderate to severe active rheumatoid arthritis. The endpoint measured the reduc...